Treatment of Ba/F3 KIF5B–RETWT allograft tumors with vepafestinib (12.5, 25, 50 mg per kg BID) resulted in dose-dependent inhibition of tumor growth (Fig. 7a) without any body weight changes (Extended Data Fig. 8e). This evidence concerns the gene KIF5B and neoplasm.